Hexarelin (also called examorelin) is a synthetic hexapeptide belonging to the growth hormone releasing peptide (GHRP) family. Its structure is derived from met-enkephalin analogs and incorporates non-natural residues, including a 2-methyl-D-tryptophan, that confer metabolic stability and potent secretagogue activity in preclinical models.
It is studied both as a growth hormone secretagogue and as a ligand with reported activity at receptors beyond the pituitary, including cardiac tissue.
Hexarelin acts primarily as an agonist at the growth hormone secretagogue receptor (GHS-R1a), the receptor for ghrelin, stimulating pulsatile growth hormone release from pituitary somatotrophs in preclinical models.
Research also describes binding to the scavenger receptor CD36 in cardiovascular tissue, a pathway investigated for effects on myocardial signaling independent of growth hormone release.
Growth hormone secretion — studied as a potent GHS-R1a agonist stimulating GH release in animal and cell models [1].
Cardiovascular signaling — investigated for CD36-mediated effects on cardiac tissue in preclinical models [2].
Cardioprotection research — examined in ischemia and cardiomyocyte models [3].
Neuroendocrine regulation — explored for interactions with the ghrelin/GHS-R system [1].
Receptor pharmacology — characterized for binding profile and desensitization in secretagogue research [1].
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.
In neuroendocrine studies, researchers administered hexarelin in animal models and measured the magnitude and duration of growth hormone release compared with other secretagogues [1].
In cardiovascular preclinical work, investigators studied hexarelin binding to CD36 and measured signaling responses in cardiac tissue and cardiomyocyte models [2]. Additional studies examined hexarelin in models of myocardial ischemia and reported observations on cardiac parameters [3]. These are study observations, reported here for reference only.
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
TesamorelinSynergistic
GHRH analogs and GHRP peptides are studied together for complementary effects on growth hormone secretion.
GHRP-2Neutral
A closely related GHRP-family secretagogue; typically compared for potency rather than combined.
CJC-1295Synergistic
GHRH-analog plus GHRP pairing is a common growth hormone research paradigm.
IpamorelinNeutral
Same secretagogue class with a more selective profile; usually studied comparatively.
Citations below are retrieved automatically from PubMed (NIH / U.S. National Library of Medicine) for the search term “Hexarelin”, newest first. They are listed as literature references for research purposes only. K4 Elite does not summarise, interpret or endorse their findings.
It is a non-natural agonist at the ghrelin receptor (GHS-R1a), which is why it is grouped with ghrelin-mimetic research compounds.
Is this material intended for human use?
No. This entry describes a compound supplied strictly for in-vitro and laboratory research use only, not for human or veterinary use.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.
K4 Elite